财务表现 - 第二季度总收入为2140万美元，同比下降9%[2] - 总毛利率为86%，与上年同期持平[2] - 现金使用量减少29%至910万美元，反映了持续的运营纪律[3] - 公司2024年上半年总收入为40.635亿美元，同比下降4.0%[30] - 公司2024年上半年净亏损为2.8595亿美元[31] 业务表现 - 手术性青光眼订单账户使用率和活跃账户数量均同比增加5%[4] - 公司2024年第二季度外科性青光眼活跃客户数为1,131家[35] - 公司2024年第二季度干眼治疗设备销量为4,088台[35] - 公司2024年第二季度干眼业务活跃客户数为277家[35] - 外科性青光眼业务收入为38.501亿美元，占总收入的94.7%[32] - 外科性青光眼业务毛利率为88.0%，同比略有下降[32] - 干眼业务收入为2.134亿美元，占总收入的5.3%[32] - 干眼业务毛利率为44.4%，同比下降10个百分点[32] 未来规划 - 公司计划于2024年10月1日提高TearCare产品价格至每套1200美元[5] - 公司预计2024年全年收入约为8100万美元至8300万美元，增长0%至2%[18] - 公司预计2024年全年调整后营业费用约为1.07亿美元至1.09亿美元，下降1%至3%[19] - 公司预计手术性青光眼业务在2024年下半年将实现两位数收入增长[17] - 公司预计干眼业务收入在2024年将低于300万美元，此后将在2025年恢复增长[18] - 公司将继续推进临床和市场准入进展，以确保TearCare技术的价值得到适当分配[10] 公司调整 - 公司2024年上半年调整后营业费用为53.19亿美元，同比下降13.0%[33]

MENLO PARK, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the second quarter ended June 30, 2024, after the market close on Thursday, August 1, 2024. The Company's management will discuss the results during a conference call beginning at 1:30 ...

MENLO PARK, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that it has published its first Sustainability Report, highlighting the Company’s sustainability activities, performance, and results from the last three years. “We are proud to issue our first annual Sustainability Repor ...

MENLO PARK, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that it has published its first Sustainability Report, highlighting the Company’s sustainability activities, performance, and results from the last three years. “We are proud to issue our first annual Sustainability Repor ...

MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the publication of the twelve-month results from the SAHARA trial. Patients previously treated with Restasis® (cyclosporine ophthalmic emulsion 0.05%) prescription eyedrops ("Restasis") had additional ...

MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the publication of the twelve-month results from the SAHARA trial. Patients previously treated with Restasis® (cyclosporine ophthalmic emulsion 0.05%) prescription eyedrops ("Restasis") had additional ...

MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the results as published in the journal Clinical Ophthalmology of a new analysis of the ROMEO (Retrospective, Observational, Multicenter Evaluation of OMNI) study data. This new analysis evaluated the as ...

MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the results as published in the journal Clinical Ophthalmology of a new analysis of the ROMEO (Retrospective, Observational, Multicenter Evaluation of OMNI) study data. This new analysis evaluated the a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 001-40587 SIGHT SCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 80-0625749 (St ...

Sight Sciences, Inc. (NASDAQ:SGHT) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul Badawi - Co-Founder and Chief Executive Officer Alison Bauerlein - Chief Financial Officer Matthew Link - Chief Commercial Officer Conference Call Participants David Saxon - Needham & Company James Beers - William Blair Thomas Stephan - Stifel Operator Good day, and thank you for standing by. Welcome to the Sight Sciences First Quarter 2024 Earnings Res ...